Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?

Dominique Elias; Charles Honoré; Diane Goéré; Leonor Benhaim; David Malka; Valérie Boige; Michel Ducreux

doi:10.1007/s11888-015-0263-8

Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?

Dominique Elias
, Charles Honoré
, Diane Goéré
, Leonor Benhaim
, David Malka
, Valérie Boige
, Michel Ducreux

Institut Gustave Roussy

Research output: Contribution to journal › Review article › peer-review

Abstract

The presence of limited and resectable extrahepatic metastases (EHM) in addition to colorectal liver metastases (LM) is no longer a contraindication to surgery. Long-term survival (between 25 and 30 % at 5 years) is possible for highly selected patients. The site of occurrence is a key prognostic factor. Results are best for lung EHM and limited peritoneal metastases (PM), lower when EHM invade the proximal hepatic lymph nodes, and worse for other EHM. Treatment decision making is difficult when faced with an infinite number of possible combinations between the different sites of metastases, their number, and the overall tumor load. General performance status, technical contingency, and chemosensitivity are also important factors to be reckoned with. In the future, a considerable amount of data concerning these patients and new statistical tools will be required to create clear decision trees.

Original language	English
Pages (from-to)	78-83
Number of pages	6
Journal	Current Colorectal Cancer Reports
Volume	11
Issue number	2
DOIs	https://doi.org/10.1007/s11888-015-0263-8
State	Published - 1 Apr 2015
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2015, Springer Science+Business Media New York.

Funding

David Malka has received research support through grants from Amgen and Merck Serono; has received honoraria from Roche, Amgen, Celgene, Sanofi-Aventis, Teva, Boehringer-Ingelheim, Menarini, Merck Serono, Bayer, and Lilly; and has received nonfinancial support from Roche, Sanofi-Aventis, and Merck Serono.

Funders
Amgen
Roche
Sanofi
EMD Serono
Teva Pharmaceutical Industries
Celgene

Keywords

Colorectal
Concomitant metastases
Extrahepatic disease
Extrahepatic metastases
Liver metastases
Lung metastases
Lymph node metastases
Nomogram
Peritoneal metastases

Access to Document

10.1007/s11888-015-0263-8

Cite this

@article{476e0bab9f064b0db7617c030425be0e,

title = "Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?",

abstract = "The presence of limited and resectable extrahepatic metastases (EHM) in addition to colorectal liver metastases (LM) is no longer a contraindication to surgery. Long-term survival (between 25 and 30 \% at 5 years) is possible for highly selected patients. The site of occurrence is a key prognostic factor. Results are best for lung EHM and limited peritoneal metastases (PM), lower when EHM invade the proximal hepatic lymph nodes, and worse for other EHM. Treatment decision making is difficult when faced with an infinite number of possible combinations between the different sites of metastases, their number, and the overall tumor load. General performance status, technical contingency, and chemosensitivity are also important factors to be reckoned with. In the future, a considerable amount of data concerning these patients and new statistical tools will be required to create clear decision trees.",

keywords = "Colorectal, Concomitant metastases, Extrahepatic disease, Extrahepatic metastases, Liver metastases, Lung metastases, Lymph node metastases, Nomogram, Peritoneal metastases",

author = "Dominique Elias and Charles Honor{\'e} and Diane Go{\'e}r{\'e} and Leonor Benhaim and David Malka and Val{\'e}rie Boige and Michel Ducreux",

note = "Publisher Copyright: {\textcopyright} 2015, Springer Science+Business Media New York.",

year = "2015",

month = apr,

day = "1",

doi = "10.1007/s11888-015-0263-8",

language = "אנגלית",

volume = "11",

pages = "78--83",

journal = "Current Colorectal Cancer Reports",

issn = "1556-3790",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Hepatic Resection for Extrahepatic Metastatic Disease

T2 - When Is It Reasonable?

AU - Elias, Dominique

AU - Honoré, Charles

AU - Goéré, Diane

AU - Benhaim, Leonor

AU - Malka, David

AU - Boige, Valérie

AU - Ducreux, Michel

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The presence of limited and resectable extrahepatic metastases (EHM) in addition to colorectal liver metastases (LM) is no longer a contraindication to surgery. Long-term survival (between 25 and 30 % at 5 years) is possible for highly selected patients. The site of occurrence is a key prognostic factor. Results are best for lung EHM and limited peritoneal metastases (PM), lower when EHM invade the proximal hepatic lymph nodes, and worse for other EHM. Treatment decision making is difficult when faced with an infinite number of possible combinations between the different sites of metastases, their number, and the overall tumor load. General performance status, technical contingency, and chemosensitivity are also important factors to be reckoned with. In the future, a considerable amount of data concerning these patients and new statistical tools will be required to create clear decision trees.

AB - The presence of limited and resectable extrahepatic metastases (EHM) in addition to colorectal liver metastases (LM) is no longer a contraindication to surgery. Long-term survival (between 25 and 30 % at 5 years) is possible for highly selected patients. The site of occurrence is a key prognostic factor. Results are best for lung EHM and limited peritoneal metastases (PM), lower when EHM invade the proximal hepatic lymph nodes, and worse for other EHM. Treatment decision making is difficult when faced with an infinite number of possible combinations between the different sites of metastases, their number, and the overall tumor load. General performance status, technical contingency, and chemosensitivity are also important factors to be reckoned with. In the future, a considerable amount of data concerning these patients and new statistical tools will be required to create clear decision trees.

KW - Colorectal

KW - Concomitant metastases

KW - Extrahepatic disease

KW - Extrahepatic metastases

KW - Liver metastases

KW - Lung metastases

KW - Lymph node metastases

KW - Nomogram

KW - Peritoneal metastases

UR - https://www.scopus.com/pages/publications/84939995356

U2 - 10.1007/s11888-015-0263-8

DO - 10.1007/s11888-015-0263-8

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:84939995356

SN - 1556-3790

VL - 11

SP - 78

EP - 83

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

IS - 2

ER -

Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this